Alladapt Immunotherapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Menlo Parkcaliforniafounded In 2018 By Ashley Dombkowskiph D And Kari Nadeaum D Ph D The Company Focuses On Developing Prescription Therapeutics For Food Allergiesalladapt Specializes In Oral Immunotherapyoitand Is Advancing Its Lead Product Candidateadp101This Investigational Therapy Aims To Treat Both Monoand Multi Food Allergiesaddressing The Nine Food Groups That Cause Most Significant Allergic Reactions Worldwidethe Company Has Conducted A Phase 1 2 Harmony Study To Evaluate The Efficacy And Safety Of Adp101Along With An Ongoing Encore Study To Assess Its Long Term Useadp101 Has Also Received Fda Fast Track Designationwhich Supports Its Expedited Developmentalladapt Has Successfully Raised $229 Million In Funding From Various Investorspositioning Itself As A Key Player In The Food Allergy Treatment Landscape
